WARSAW, Ind.--(BUSINESS WIRE)--May 3, 2006--Biomet (NASDAQ:BMET - News) announced today that the U.S. Food & Drug Administration has issued regulatory clearance for the Company’s Regenerex(TM) Porous Titanium Construct acetabular system for primary and revision hip surgery. Regenerex(TM) Porous Titanium Construct is a highly porous structural material engineered for optimal biological fixation. The system includes acetabular shells and augments designed to address complex revision procedures. The product launch is scheduled to begin during the first half of fiscal year 2007.
